J
The part I bolded shows that even the study authors do not consider these results sufficient to recommend non-study use of HCQ.Dr. Zervos also pointed out, as does the paper, that the study results should be interpreted with some caution, should not be applied to patients treated outside of hospital settings and require further confirmation in prospective, randomized controlled trials that rigorously evaluate the safety and efficacy of hydroxychloroquine therapy for COVID-19.
“Currently, the drug should be used only in hospitalized patients with appropriate monitoring, and as part of study protocols, in accordance with all relevant federal regulations,” Dr. Zervos said.
In this multi-hospital assessment, when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with REDUCTION in COVID-19 associated mortality. Prospective trials are needed to examine this impact.
And if I’m not mistaken that was one of the arguments used in previous discussions on CAF regarding the effective use of hydroxychloroquine, that is, it needed to be used in the earlier stages of the disease.Dr. Marcus Zervos, division head of infectious disease for Henry Ford Health System, said 26% of those not given hydroxychloroquine died, compared to 13% of those who got the drug. The team looked back at everyone treated in the hospital system since the first patient in March.
“Our results do differ from some other studies,” Zervos told a news conference. “What we think was important in ours … is that patients were treated EARLY. For hydroxychloroquine to have a benefit, it needs to begin before the patients begin to suffer some of the severe immune reactions that patients can have with Covid,” he added.
That last paragraph is very important. What it says is that the patients who received HCQ were also mostly the ones who received the steroid dexamethasone, which suggests that perhaps the inflammation-fighting properties of the steroid was what actually accounted for the reduction in death rates, and not the HCQ. Or maybe it was the combination of HCQ and the steroid. We don’t know. The point is the result is promising, but not definitive. The researchers and the media were correct in tamping down the exaggerated enthusiasm for HCQ. That is not to say that HCQ definitely doesn’t work. Perhaps some combination of HCQ and something else will turn out to be the “game changer” that Trump predicted. I hope so. But we just don’t know yet. However we do know that standard treatment is getting better and better as we learn more about this virus. The death rate as a fraction of the hospitalization rate has gone down overall. That is good news.Researchers not involved in the Henry Ford study pointed out it wasn’t of the same quality of the studies showing hydroxychloroquine did not help patients, and said other treatments, such as the use of the steroid dexamethasone, might have accounted for the better survival of some patients.
. . .
“As the Henry Ford Health System became more experienced in treating patients with COVID-19, survival may have improved, regardless of the use of specific therapies,” Dr. Todd Lee of the Royal Victoria Hospital in Montreal, Canada, and colleagues wrote in a commentary in the same journal.
“Finally, concomitant steroid use in patients receiving hydroxychloroquine was more than double the non-treated group. This is relevant considering the recent RECOVERY trial that showed a mortality benefit with dexamethasone.” The steroid dexamethasone can reduce inflammation in seriously ill patients.
“Tamping down . . . enthusiasm” is not the role of researchers.The researchers and the media were correct in tamping down the exaggerated enthusiasm for HCQ.
This was turned into a political football as soon as Trump said a positive word about it. To many in the media, and likewise some posters here, anything that Trump says is good must inherently be bad.This is what I don’t get… why the heck is a DRUG a conservative vs liberal issue? To me that is literally INSANE. If this wasn’t a matter of lives on the line, it would be laughable. Of all the things to make a political issue…
Actually…it kind of is. It is good science to point out the flaws of your research, thus “tamping down” enthusiasm. Leaf has done a good job in explaining some of the deficiencies in this research. However, everyone should understand that most ALL medical research has significant flaws, yet we are only given what knowledge we are given, so we use it.“Tamping down . . . enthusiasm” is not the role of researchers.
The role of the press has been to denigrate President Trump since he won the Republican nomination.Tamping down . . . enthusiasm” is also not the role of the press.
No, it means perhaps you can stop with the useless inflammatory posts like this. But you won’t, because it’s about all you have to contribute.Does this mean we should at least give a second look at injecting bleach or opening lungs to expose them to UV light…Why not? “You have nothing to lose!”
That wasn’t the only explanation:Talk about cherry-picking, the doctor involved in the study explains why their results were different from previous studies:
While there was a hospital treatment protocol in place, unmeasured clinical factors likely influenced the decision not to treat 16.1% of patients, in a center where 78% received treatment. These factors are often difficult to capture in an observational study. Were the decision to withhold treatment related to poor prognosis (e.g. palliative intent), it stands to reason that patients receiving neither hydroxychloroquine nor azithromycin would have the highest mortality. Indeed, the non-treated group had an overall mortality that was higher than the rate of admission to the ICU (26.4% vs. 15.2%), suggesting that many patients were not considered appropriate for critical care.